Bluejay Diagnostics (BJDX) Stock Price, News & Analysis

Company Overview

Bluejay Diagnostics, Inc. is a medical technology company developing rapid, near-patient diagnostic solutions for use in hospitals and other care settings. The company’s focus is on helping clinicians obtain actionable information from small blood samples without relying exclusively on centralized laboratory testing.

Its primary product platform, the Symphony System, combines a reusable analyzer with disposable test cartridges designed to analyze whole-blood biomarkers. The platform’s initial focus has been the Symphony IL-6 Test, which measures interleukin-6, an inflammatory biomarker associated with immune-system activation and conditions such as sepsis. The test is intended to support clinical assessment and patient-management decisions rather than replace a physician’s diagnosis.

Bluejay Diagnostics is based in Waltham, Massachusetts, and has focused its commercial and development efforts on the U.S. healthcare market. The company’s technology is designed for use in emergency departments, intensive-care units and other settings where timely biomarker results may help guide treatment. Information about its current leadership and broader international operations is limited.

Key Stats

• Today's Range: $0.91 to $0.96
• 50-Day Range: $0.81 to $1.24
• 52-Week Range: $0.80 to $16.68
• Volume: 286,032 shs
• Average Volume: 3.40 million shs
• Market Capitalization: $4.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Bluejay Diagnostics Stock Analysis - MarketRank™

Bluejay Diagnostics scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Bluejay Diagnostics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Bluejay Diagnostics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Bluejay Diagnostics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bluejay Diagnostics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bluejay Diagnostics has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.13% of the float of Bluejay Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Bluejay Diagnostics has a short interest ratio ("days to cover") of 0.03, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bluejay Diagnostics has recently decreased by 50.41%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bluejay Diagnostics does not currently pay a dividend.

Dividend Growth

Bluejay Diagnostics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.39

News Sentiment

Bluejay Diagnostics has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Bluejay Diagnostics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for BJDX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

2 people have added Bluejay Diagnostics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $47,798.00 in company stock, which represents 1.1606% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Bluejay Diagnostics insiders have bought 97.72% more of their company's stock than they have sold. Specifically, they have bought $96,711.00 in company stock and sold $48,913.00 in company stock.

Percentage Held by Insiders

6.10% of the stock of Bluejay Diagnostics is held by insiders.

Percentage Held by Institutions

18.47% of the stock of Bluejay Diagnostics is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/26/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:BJDX
• CIK: 1704287
• Web: www.bluejaydx.com
• Phone: 844-327-7078
• Fax: N/A
• Employees: 6
• Year Founded: 2015

Profitability

• EPS (Trailing Twelve Months): ($7.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -125.00%
• Return on Assets: -99.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.64
• Quick Ratio: 4.64

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.43 per share
• Price / Book: 0.11

Miscellaneous

• Outstanding Shares: 4,470,000
• Free Float: 4,195,000
• Market Cap: $4.12 million
• Optionable: Not Optionable
• Beta: 0.91